InsiderSignal.AI

InsiderSignal.ai

CNC - Centene Corp

Insider Purchase by London Sarah (CEO)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, London Sarah, serving as CEO at Centene Corp (CNC), purchased 19,230 shares at $25.50 per share, for a total transaction value of $490,365.00. Following this transaction, London Sarah now holds 845,275 shares of CNC.

This purchase represents a 2.00% increase in London Sarah's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, August 8, 2025 and publicly disclosed via SEC Form 4 filing on Monday, August 11, 2025, 3 days after the trade was made.

Centene Corp operates in the HEALTHCARE sector, specifically within the HEALTHCARE PLANS industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

London Sarah

CEO

Sarah M. London (née McGinty, born 1979/1980) is the Chief Executive Officer of Centene Corporation (NYSE: CNC), a Fortune 25 healthcare company focused on government-sponsored programs serving over 26 million under-insured and uninsured Americans.[[1]](https://investors.centene.com/2022-03-22-CENTENE-APPOINTS-SARAH-LONDON-AS-CHIEF-EXECUTIVE-OFFICER)[[2]](https://www.healthevolution.com/bios/speaker/sarah-london/)[[6]](https://milkeninstitute.org/events/future-health-summit-2025/speakers/sarah-london) Appointed CEO on March 22, 2022, succeeding Michael Neidorff, she previously served as Vice Chairman, leading technology, digital strategy, Health Care Enterprises, Specialty divisions, Corporate Strategy, Quality Operations, Internal Audit, Compliance, and Risk Management.[[1]](https://investors.centene.com/2022-03-22-CENTENE-APPOINTS-SARAH-LONDON-AS-CHIEF-EXECUTIVE-OFFICER)[[2]](https://www.healthevolution.com/bios/speaker/sarah-london/) London has driven innovation in value-based care through data-driven insights and technology.[[1]](https://investors.centene.com/2022-03-22-CENTENE-APPOINTS-SARAH-LONDON-AS-CHIEF-EXECUTIVE-OFFICER) London's career spans healthcare innovation, starting at Health Leads addressing social determinants of health, followed by launching Accretive Health's Quality & Total Cost of Care business, roles at Humedica (acquired by Optum), Chief Product Officer at Optum Analytics, and Partner at Optum Ventures before joining Centene in 2020.[[1]](https://investors.centene.com/2022-03-22-CENTENE-APPOINTS-SARAH-LONDON-AS-CHIEF-EXECUTIVE-OFFICER)[[2]](https://www.healthevolution.com/bios/speaker/sarah-london/) She holds a B.A. magna cum laude in history and literature from Harvard College, where she played Division I tennis, and an M.B.A. with High Honors from the University of Chicago Booth School of Business.[[2]](https://www.healthevolution.com/bios/speaker/sarah-london/)[[3]](https://en.wikipedia.org/wiki/Sarah_London) Recognized as the youngest female Fortune 500 CEO, she ranked No. 40 on Fortune's 2023 Most Powerful Women list and was named a Top Women Leader in Healthcare by Modern Healthcare.[[4]](https://www.buckeyehealthplan.com/providers/updates11/october-2023-updates/ceo-sarah-london-named-one-of-fortune-s-2023-most-powerful-women.html)

View full insider profile →

Trade Price

$25.50

Quantity

19,230

Total Value

$490,365.00

Shares Owned

845,275

Trade Date

Friday, August 8, 2025

198 days ago

SEC Filing Date

Monday, August 11, 2025

Filed 3 days after trade

HEALTHCAREHEALTHCARE PLANS

About Centene Corp

Company Overview

No company information available
View news mentioning CNC

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/120924

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime